Mepazine

CHEMBL395110 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

310.5 g/mol

LogP

5.6

Phase

4

A phenothiazine antipsychotic used to treat schizophrenia and other psychotic disorders. It works by blocking dopamine receptors in the brain to reduce symptoms such as hallucinations and delusions.

Molecular Weight

310.5000 g/mol

LogP

5.60

TPSA

31.80 Å²

Lipinski RO5

Pass

Mechanism of Action

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1

InChI

InChI=1S/C19H22N2S/c1-20-12-6-7-15(13-20)14-21-16-8-2-4-10-18(16)22-19-11-5-3-9-17(19)21/h2-5,8-11,15H,6-7,12-14H2,1H3

Molecular Formula

C19H22N2S

HBD / HBA

- / 3

Rotatable Bonds

2

Heavy Atoms

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A phenothiazine antipsychotic used to treat schizophrenia and other psychotic disorders. It works by blocking dopamine receptors in the brain to reduce symptoms such as hallucinations and delusions.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Mepazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL395110. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6075. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Mepazine on PillFYI

Structure

Quick Data

Formula: C19H22N2S

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.